Accupril: profile and news

Alba Therapeutics Announces Creation of Development Advisory Board 06 Mar 2006
...of Clinical Pharmacology at Parke Davis, he oversaw the exploratory clinical development of drugs such as Neurontin®, Lipitor® and Accupril® and following a ... - Yahoo! News (press release)

Pfizer 2006 profit view disappoints, stock falls Feb 10, 2006
Fourth-quarter sales of the epilepsy treatment Neurontin plunged 71 percent to $141 million; sales of hypertension drug Accupril fell 74 percent to $44 million ... - Reuters

Pfizer Fourth-Quarter and Full-Year 2005 Financial Results Reflect ... Jan 19, 2006
...$13,101 (11) $44,284 $46,133 (4) Celebrex 472 1,008 (53) 1,730 3,302 (48) Bextra (2) 417 * (61) 1,286 * Dynastat 8 14 (44) 34 46 (25) Accupril/Accuretic 44 165 ... - PR Newswire (press release),

Pfizer quarter beats forecasts Jan 19, 2006
Epilepsy treatment Neurontin saw sales slump 71%, hypertension drug Accupril sank 74%, while sales of arthritis treatment Celebrex tumbled 53% following the ... - Life Style Extra,

Pfizer quarterly profit falls, mauled by generics Jan 19, 2006
They include epilepsy treatment Neurontin, whose fourth-quarter sales plunged 71 percent to $141 million, and hypertension drug Accupril, which fell 74 percent ... - ABC News

Heart drug use has increased, but still suboptimal Jan 9, 2006
In 2002, rates of overall and consistent use of angiotensin-converting enzyme (ACE) inhibitors, such as Accupril and Vasotec, in patients with heart failure ... - Reuters.uk,

Pfizer profit falls, but drugmaker beats forecast Jan 19, 2006
They include epilepsy treatment Neurontin, whose fourth-quarter sales plunged 71 percent to $141 million, hypertension drug Accupril, which fell 74 percent to ... - Reuters India,

Ranbaxy hit, low US prices pinch Indian drugmakers Jan 17, 2006
November, a US court upheld a ruling blocking sales by Ranbaxy and world-leading generic maker Teva of generic alternatives to Pfizer's Accupril blood pressure ... - Boston Globe,

Ranbaxy net hit by price pressure, gets new CEO Jan 18, 2006
November also upheld a preliminary district court injunction barring Ranbaxy from selling quinapril tablets - a generic of Pfizer's blood pressure drug Accupril ... - Reuters India,

Heart patients don't stick to drug programs Jan 10, 2006
In 2002, rates of overall and consistent use of ACE inhibitors, such as Accupril and Vasotec, in patients with heart failure were 51 percent and 39 percent ... - News-Medical.net,

DemiDose(TM) Pill Splitter Allays Concern Over Dose Accuracy in ... Jan 11, 2006
...medications on the market today, including: Thyroid Heart - Blood Pressure Erectile Dysfunction Cholesterol - Synthroid - Accupril - Viagra - Lipitor - Norvasc ... - PR Newswire (press release),

New plan cuts many from meds Jan 21, 2006
A lot of ailments. He laughs and pulls a card out of his wallet. On it is a list, including Accupril, Norvase, Macomist and Zoloft. ... - Times Herald-Record,

Accupril gives another blow to Ranbaxy Nov 23, 2005
...the Federal Circuit upheld the decision of a lower court stopping the Indian company and Teva Pharmaceuticals Ltd from selling generic form of Pfizer's Accupril ... - Financial Express,

CAFC Upholds Preliminary Injunction Against Ranbaxy and Teva Dec 1, 2005
US Court of Appeals for the Federal Circuit (CAFC) upheld a ruling which blocked sales of Ranbaxy's generic alternative to Pfizer Inc's Accupril blood pressure ... - Patent Baristas,

Pfizer wins ruling on blood pressure medicine Nov 23, 2005
...index this year, fell as much as 3.2 percent after Pfizer Inc won a court ruling barring rivals from selling copies of blood pressure medicine Accupril in the ... - Shanghai Daily,

Pfizer marks another win against generic drugs Nov 23, 2005
...a preliminary injunction late yesterday prohibiting India’s Ranbaxy from selling a generic version of Pfizer’s high blood pressure treatment, Accupril. ... - Crain's New York Business,

Court upholds injunction against Teva, Ranbaxy Nov 22, 2005
A US appeals court on Tuesday upheld a ruling blocking sales of generic alternatives to Pfizer Inc.'s (PFE.N: Quote, Profile, Research) Accupril blood pressure ... - Reuters

Blood pressure drug...Ranbaxy loses case to Pfizer Nov 23, 2005
...on Wednesday that a US appeals court has granted an injunction against its proposed launch of a generic version of Pfizer Inc.'s blood pressure drug Accupril. ... - India Infoline.com,

AstraZeneca, Pfizer boost pharma stocks; Alexion drops Nov 23, 2005
...stocks inched into positive territory Wednesday, prodded largely by positive developments in patent lawsuits involving Pfizer's Accupril and AstraZeneca's ... - Investor's Business Daily (subscription)

AstraZeneca, Pfizer boost pharma stocks Nov 23, 2005
Pharmaceutical stocks closed slightly higher Wednesday, prodded by upbeat developments in patent lawsuits involving Pfizer's Accupril and AstraZeneca's Nexxium ... - Investor's Business Daily (subscription)

Court backs Pfizer on generic dispute Nov 22, 2005
A federal appeals court on Tuesday upheld an injunction preventing the launch of a generic version of Pfizer's blood-pressure drug Accupril, also known as ... - MarketWatch

US court upholds injunction against Teva, Ranbaxy Nov 22, 2005
WASHINGTON (Reuters) - A federal appeals court on Tuesday upheld a ruling blocking sales of generic alternatives to Pfizer Inc.'s Accupril blood pressure drug. ... - Reuters India,

Pfizer wins patent suit against Teva Nov 22, 2005
The drug, sold by Pfizer as Accupril, is used to treat high blood pressure and heart failure. The drug is made by Ranbaxy and marketed by Teva. ... - United Press International

Garden State Business Briefs Nov 22, 2005
A federal appeals court yesterday upheld a ruling blocking sales of generic alternatives to Pfizer's blood-pressure drug Accupril. ... - Newark Star Ledger,

Injunction against RLL's generic drug upheld Nov 23, 2005
A US federal appeals court has upheld a ruling that sought to block sales of generic alternatives to Pfizer Inc's Accupril blood pressure drug, produced by ... - Webindia123,

Sensex scales new peak above 8,800 Nov 25, 2005
...on a weak note over the past few days after a US appeals court upheld a ruling that blocked sales of generic versions of Pfizer's blood pressure drug Accupril. ... - Economic Times,

Sensex ends 103 pts up at close Nov 23, 2005
...of sustained selling pressure following a US appeals court upholding a ruling blocking sales of generic alternatives to Pfizer Inc's Accupril blood pressure ... - Sify,

Sensex vaults 106 pts at close Nov 24, 2005
Ranbaxy Laboratories slipped once again, the recent verdict by a US court blocking sales of generic alternatives to Pfizer Inc's Accupril blood pressure drug ... - Sify,

Injunction against RLL’s generic drug upheld Nov 23, 2005
Court of Appeals for the Federal Circuit on Tuesday upheld a ruling that sought to block sales of generic alternatives to Pfizer Inc.'s Accupril blood pressure ... - Sify,

US court rules against Ranbaxy in Quinapril case Nov 22, 2005
Quinapril HCI tablets are the AB-rated generic equivalent of Pfizer's anti-hypertensive agent Accupril tablets, the release said. ... - Business Standard,

Ranbaxy loses US court battle, barred from marketing drug Nov 23, 2005
...today. Quinapril HCI tablets are the AB-rated generic equivalent of Pfizer (Parke Davis) anti-hypertensive agent Accupril tablets. ... - Hindu Business Line,

Ranbaxy barred from selling drug in US Nov 23, 2005
Exchange. Quinapril HCI Tablets are the AB-rated generic equivalent of Pfizer (Parke Davis) antihypertensive agent Accupril tablets. ... - Economic Times,

Ranbaxy Challenges Drug Patent Nov 24, 2005
...imposed the preliminary injunction in March against Ranbaxy’s Jacksonville, Florida-based subsidiary after Pfizer, which sold the drug as Accupril, filed a ... - Red Herring,

Sensex up 71.69 pts @ 11:40 hrs Nov 23, 2005
...tumbled to a low of Rs 356.90 following a US appeals court upholding a ruling blocking sales of generic alternatives to Pfizer Inc's Accupril blood pressure ... - Sify,

US court upholds stand against Ranbaxy, Teva Nov 23, 2005
...on the $500 million drug had been given by the US District Court on a patent infringement suit filed by the innovator Pfizer Inc which sold it as ‘Accupril ... - Business Standard,

Biotech Stocks Drug stocks mixed as Pain Therapeutics tanks Nov 22, 2005
...injunction issued by a lower court that prevents Ranbaxy and Teva Pharmaceutical Industries from selling their generic version of Pfizer's Accupril until their ... - MarketWatch

US court upholds bar on Ranbaxy’s quinapril sale Nov 23, 2005
...said. Quinapril HCI tablets are the AB-rated generic equivalent of Pfizer (Parke Davis) anti-hypertensive agent accupril tablets. ... - Economic Times,

Indian shares rise after two-day fall Nov 22, 2005
...was down 2 percent at 369.35 rupees after an US appeals court granted an injunction against launch of generic version of Pfizer Inc.'s Accupril. ... - Reuters India,

Market Report / Banks spur steep gains Nov 24, 2005
AUS federal appeals court found for Pfizer, blocking sales of Teva's generic version of blood pressure drug Accupril, which Teva had already released in an "at ... - Ha'aretz (subscription),

Indian stocks gain ground ahead of futures expiry Nov 23, 2005
...to 365.95 rupees after a US federal appeals court on Tuesday upheld a ruling blocking sales of generic alternatives to Pfizer Inc.'s Accupril blood pressure ... - Reuters India,

US court rules against Ranbaxy, supports Pfizer patent Nov 24, 2005
Appeals for the Federal Circuit Wednesday affirmed Judge Dickinson R Debevoise's earlier order to stop selling a generic version of Pfizer's Accupril drug by ... - New Ratings

- By Our Correspondent Nov 23, 2005
...infringement case. Quinapril HCl tablets are the AB-rated generic equivalent of Pfizer antihypertensive agent accupril tablets. - The Asian Age,

Pfizer CEO sees Celebrex rebound Nov 7, 2005
Company sales have also been hurt by generic competition for its Diflucan anti-fungal drug, epilepsy treatment Neurontin and Accupril for high blood pressure. ... - Leading The Charge,

FIFTH ANNUAL SPECIAL FEATURE: Most Admired Companies Oct 20, 2005
...for certain products. Neurontin, Diflucan, and Accupril were subject to generic competition in the latter part of 2004. Last year ... - Med Ad News (subscription),

Earnings Outlook Big week for Big Pharma Oct 13, 2005
...said that Pfizer's earnings will also reflect heightened generic competition against such once-lucrative drugs as Neurontin, Diflucan and Accupril, as well as ... - MarketWatch

Obama against review of stress disorder cases Oct 2, 2005
ACE (angiotensin converting enzyme) inhibitors for treatment of hypertension. Brand names: Altace, Aceon, Accupril and Univasc. ... - Daily Press,

Bharat Forge: Forging ahead Oct 7, 2005
On the positive side, Ranbaxy could benefit from potential upsides like the launch of generic Lipitor, a favourable ruling on Accupril, exclusivity for generic ... - Business Standard,

Pfizer's Accupril no help after bypass surgery Sep 5, 2005
STOCKHOLM (Reuters) - Giving Pfizer Inc.'s drug Accupril to patients who have recently had bypass surgery provides no benefit, researchers said on Monday. ... - Reuters

US appeals court sends Accupril patent case back Aug 11, 2005
...said a lower court had erred in granting summary judgment in favor of Pfizer (PFE.N: Quote, Profile, Research) for a patent on its Accupril blood pressure drug ... - Reuters

UPDATE 1-US appeals court sends Accupril patent case back Aug 11, 2005
...(PFE.N: Quote, Profile, Research) for a patent on its Accupril drug to treat high blood pressure, sending the case back for further review. ... - Reuters

US appeals court sends Accupril patent case back Aug 11, 2005
...for a patent on its Accupril drug to treat high blood pressure, sending the case back for further review. ... from marketing generic Accupril. ... - Reuters India,

IMAGINE shows important new findings in the early phase post-CABG ... Sep 6, 2005
The IMAGINE (Ischemia Management with Accupril post bypass Graft via Inhibition of angiotensive coNverting Enzyme) study results are presented at the European ... - Medical News Today (press release),

US appeals court sends Pfizer patent case back Aug 11, 2005
...of Pfizer Inc. for a patent on its Accupril drug to treat high blood pressure, sending the case back for further review. The US ... - Reuters India,

Big drug companies freeze hiring Aug 14, 2005
Last year, Ranbaxy had discontinued two of its marketing outsourcing arrangements in the US following a decision to stop the sales of Accupril and another ... - Business Standard,

Public Often Misunderstands Heart Failure Aug 30, 2005
Examples of these medications include Accupril, Monopril, Vasotec, and Zestril. Beta-blockers inhibit hormones that make the heart beat hard and fast. ... - WebMD

Business news in brief Aug 12, 2005
Industries Inc. infringed a Pfizer Inc. patent for the blood-pressure treatment Accupril. Teva has US headquarters in North Wales. The ... - Philadelphia Inquirer,

Bombay shares drop after hitting new high, Karachi up Aug 11, 2005
...favouring Pfizer Inc. to block sales of Ranbaxy's generic version of Accupril, a drug to treat blood pressure. * BLB Ltd. surged 10 ... - Reuters India,

Bombay shares down on high oil price, fund selling Aug 12, 2005
...to block sales of Ranbaxy's generic version of Accupril, a drug to treat blood pressure. * Sugar producer DCM Shriram Consolidated Ltd. ... - Reuters India,

Markets - Shares down on oil, fund sales; rupee firm Aug 12, 2005
...to block sales of Ranbaxy's generic version of Accupril, a drug to treat blood pressure. Infrastructure Development Finance Company Ltd. ... - Reuters India,

Sensex loses 49 points on caution over FII inflows Aug 13, 2005
...rose 3% to Rs 536 after a US appeals court reversed a previous judgement favouring Pfizer to block sales of Ranbaxy’s generic version of Accupril, a drug to ... - Economic Times,

Pfizer "overweight" Jul 13, 2005
...quarter are expected to have been adversely affected by the withdrawal of Bextra and generic competition for the company’s Neurontin, Accupril and Diflucan ... - New Ratings

Pfizer Inc Second-Quarter 2005 Performance Report Jul 20, 2005
...growth in the in-line portfolio, offset by sales declines associated with Celebrex and Bextra and generic competition to Neurontin, Diflucan, and Accupril. ... - Yahoo News (press release)

Pfizer posts 21% rise in second-quarter earnings Jul 20, 2005
Meanwhile, patent expirations drove down sales of anti-fungal treatment Diflucan and blood pressure treatment Accupril. Diflucan ... - USA Today

Generic Drug Makers Taking More Aggressive Approach Against ... Aug 2, 2005
Laboratories of India, are both embroiled in litigation against Pfizer in the United States over a generic version of Pfizer's antihypertensive drug Accupril. ... - Yahoo News (press release)

Pfizer Clears The First Hurdle Jul 20, 2005
Aside from patent expirations, which currently include Neurontin, Diflucan and Accupril and could in the not-too-distant future include Zithromax and Norvasc ... - Forbes

Pfizer reports 21% jump in profit Jul 20, 2005
...attributed the drop to the withdrawal of Bextra from the market, weakened sales for Celebrex, and generic competition for Neurontin, Diflucan and Accupril. - MarketWatch

Ranbaxy Q2 profit halves on competition, costs Jul 28, 2005
Ranbaxy said its US performance was affected by quinapril, a generic version of Pfizer's Accupril blood pressure drug, staying off the market. ... - Reuters India

Pfizer's 2nd-Qtr Net Jumps 21%, Helped by Lipitor (Update1) Jul 20, 2005
This year Pfizer confronted generic competition for Neurontin, the Diflucan anti-infective and the Accupril high blood pressure drug, which together had about ... - Bloomberg

Eye On Stocks For Wednesday, July 21 Jul 20, 2005
Earlier this month, Morgan Stanley raised its earnings estimates after a federal court judge upheld the formulation patent for Accupril and delayed the launch ... - Forbes

Pfizer's earnings increase 21% Jul 20, 2005
This year, Pfizer confronted generic competition for Neurontin, the anti-infective Diflucan and the high blood pressure drug Accupril, which together had about ... - International Herald Tribune

Pfizer's 2Q Earnings Rise 21 Percent Jul 20, 2005
Antifungal treatment Diflucan's revenue sank 55 percent to $129 million while blood pressure treatment Accupril's sales dropped 53 percent to $73 million. ... - Forbes

As with other ACE inhibitors, patients on diuretics, especially those on recently instituted diuretic therapy, may occasionally experience an excessive reduction of blood pressure after initiation of therapy with ACCUPRIL. The possibility of hypotensive effects with ACCUPRIL may be minimized by either discontinuing the diuretic or cautiously increasing salt intake prior to initiation of treatment with ACCUPRIL. If it is not possible to discontinue the diuretic, the starting dose of quinapril should be reduced.

Quinapril can attenuate potassium loss caused by thiazide diuretics and increase serum potassium when used alone. If concomitant therapy of ACCUPRIL with potassium-sparing diuretics (eg, spironolactone, triamterene, or amiloride), potassium supplements, or potassium-containing salt substitutes is indicated, they should be used with caution along with appropriate monitoring of serum potassium.

Simultaneous administration of tetracycline with ACCUPRIL reduced the absorption of tetracycline by approximately 28% to 37%, possibly due to the high magnesium content in ACCUPRIL tablets. This interaction should be considered if coprescribing ACCUPRIL and tetracycline or other drugs that interact with magnesium.

Increased serum lithium levels and symptoms of lithium toxicity have been reported in patients receiving concomitant lithium and ACE inhibitor therapy. These drugs should be coadministered with caution and frequent monitoring of serum lithium levels is recommended. If a diuretic is also used, it may increase the risk of lithium toxicity.

· Multiple dose therapy with propranolol or cimetidine has no effect on the pharmacokinetics of single doses of ACCUPRIL.

· The anticoagulant effect of a single dose of warfarin (measured by prothrombin time) was not significantly changed by quinapril coadministration twice-daily.

· No pharmacokinetic interaction was observed when single doses of ACCUPRIL and hydrochlorothiazide were administered concomitantly.

· Co-administration of multiple 10 mg doses of atorvastatin with 80 mg of ACCUPRIL resulted in no significant change in the steady-state pharmacokinetic parameters of atorvastatin.